Reimbursement policies in the Asia-Pacific for chronic hepatitis B

[1]  A. Culyer.  Pharmaceutical Management Agency , 2014 .

[2]  K. Simon,et al.  Chronic Hepatitis B Monitoring and Treatment Patterns in Five European Countries with Different Access and Reimbursement Policies , 2014, Antiviral therapy.

[3]  E. Tanaka,et al.  Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  D. Ramaekers,et al.  Evidence-Based Health Care Policy in Reimbursement Decisions: Lessons from a Series of Six Equivocal Case-Studies , 2013, PloS one.

[5]  Keat Hong Lee,et al.  Patient Preferences for Hepatitis B Therapy , 2013, Antiviral therapy.

[6]  紀夫 林,et al.  B型肝炎治療ガイドライン（第1.1版） , 2013 .

[7]  Keat Hong Lee,et al.  Are physicians following guidelines? A survey of Hepatitis B management strategies , 2013, Hepatology International.

[8]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[9]  P. Abraham.  Viral hepatitis in India. , 2012, Clinics in laboratory medicine.

[10]  H. Yim,et al.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B , 2012, Clinical and molecular hepatology.

[11]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[12]  Yu Wang,et al.  Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. , 2009, Vaccine.

[13]  P. Komolmit,et al.  Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand , 2009, Hepatology international.

[14]  M. Aung,et al.  The economics of treating chronic hepatitis B in Asia , 2008, Hepatology international.

[15]  M. Yuen,et al.  Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease , 2007, Antiviral therapy.

[16]  N. Leung,et al.  Hepatitis B: overview of the burden of disease in the Asia‐Pacific region , 2006 .

[17]  D. Lavanchy.  Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[18]  Stephen S. Lim,et al.  Evaluation of current strategies and future priorities for improving health in developing countries , 2005, BMJ : British Medical Journal.

[19]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[20]  A H Briggs,et al.  Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. , 2001, Health economics.

[21]  Michael E. Chernew,et al.  Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  A Gafni,et al.  Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[23]  Feros Pm.  The Pharmaceutical Benefits Scheme. , 1986, The Medical journal of Australia.

[24]  N. Hiramatsu,et al.  Guidelines for the Management of Hepatitis C Virus Infection , 2013 .

[25]  학회자료.  Review : KASL Clinical Practice Guidelines; Management of chronic hepatitis B , 2012 .

[26]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.